Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111692 | 0.89 | PTGER4 (0.61) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29406596 | 0.89 | PTGER4 (0.61) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15687371 | 0.88 | PTGER4 (0.52) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12000764 | 0.86 | PTGER4 (0.66) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1748943 | 0.83 | PTGER4 (0.84) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10019032 | 0.83 | PTGER4 (0.49) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12584015 | 0.82 | PTGER4 (0.47) | PTGER4PTGDRMAPTPTGER2 | |
| SCHEMBL1137560 | 0.81 | PTGER4 (0.47) | PTGER4PTGDRPTGER3KMT2AMAPT | |
| SCHEMBL30364769 | 0.81 | PTGER4 (0.56) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28942951 | 0.81 | PTGER4 (0.56) | PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013169-B1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2013169-B1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| EP-2013169-A1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121578-A1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121578-A1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 8/4885KDM4E 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.